682 related articles for article (PubMed ID: 28321813)
61. Antigen-specific immunotherapies for acute myeloid leukemia.
Buckley SA; Walter RB
Hematology Am Soc Hematol Educ Program; 2015; 2015():584-95. PubMed ID: 26637776
[TBL] [Abstract][Full Text] [Related]
62. Immunotherapy for acute myeloid leukemia.
Jurcic JG
Curr Oncol Rep; 2005 Sep; 7(5):339-46. PubMed ID: 16091194
[TBL] [Abstract][Full Text] [Related]
63. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
64. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
Amadori S; Stasi R
Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
[TBL] [Abstract][Full Text] [Related]
65. The Role of T Cell Immunotherapy in Acute Myeloid Leukemia.
Hao F; Sholy C; Wang C; Cao M; Kang X
Cells; 2021 Dec; 10(12):. PubMed ID: 34943884
[TBL] [Abstract][Full Text] [Related]
66. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
67. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
68. Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
Isidori A; Cerchione C; Daver N; DiNardo C; Garcia-Manero G; Konopleva M; Jabbour E; Ravandi F; Kadia T; Burguera AF; Romano A; Loscocco F; Visani G; Martinelli G; Kantarjian H; Curti A
Front Oncol; 2021; 11():656218. PubMed ID: 34041025
[TBL] [Abstract][Full Text] [Related]
69. CD33 BiTE
Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
[TBL] [Abstract][Full Text] [Related]
70. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
71. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
[TBL] [Abstract][Full Text] [Related]
72. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
73. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
74. Biological therapy in elderly patients with acute myeloid leukemia.
Ciotti G; Marconi G; Sperotto A; Giannini MB; Gottardi M; Martinelli G
Expert Opin Biol Ther; 2023 Feb; 23(2):175-194. PubMed ID: 36715330
[TBL] [Abstract][Full Text] [Related]
75. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
76. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
77. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
[TBL] [Abstract][Full Text] [Related]
78. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Gbadamosi M; Meshinchi S; Lamba JK
Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
[TBL] [Abstract][Full Text] [Related]
79. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
80. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
Rashidi A; Walter RB
Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
